Marta Monguió-Tortajada – VJRegenMed

EV-based therapies for myocardial infarction

Simon Ng — Wed, 19 Jan 2022 13:01:32 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, comments on utilizing extracellular vesicles (EVs) derived from mesenchymal stem cells to regenerate cardiac tissue after a myocardial infarction. EVs that were found to promote angiogenesis and reduce inflammation were identified and with a tissue-engineered scaffold, were delivered to scar tissue. After a period of 30 days, fibrosis was reduced and increased cardiac function was observed. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

The benefits of extracellular vesicle-based therapies

Simon Ng — Wed, 19 Jan 2022 13:01:30 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, discusses the advantages of using extracellular vesicles (EVs) in tissue-engineered therapies. EVs tend to require less stringent storage conditions and as they are not live, they are more stable compared to cellular therapies. They can also be formulated into a slow-release dosage, resulting in a lower dose required for administration, and in vivo models have demonstrated mesenchymal stem cell-derived EVs have an acceptable safety profile. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Highlights in extracellular vesicle research at TERMIS 2021

Simon Ng — Mon, 10 Jan 2022 16:16:57 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, provides her highlights from the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021) within the field of extracellular vesicles (EVs). Dr Monguió-Tortajada discusses novel research on certain EVs which are attached to the extracellular matrix (ECM), and how these particular EVs can influence the cell environment and other EVs within the cell. This interview took place at TERMIS 2021.

Extracellular vesicles as a source of novel biomarkers

Simon Ng — Mon, 10 Jan 2022 16:16:57 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, gives an overview of how extracellular vesicles (EVs) can be utilized to find novel biomarkers for cardiovascular diseases. EVs contain numerous molecules including proteins, microRNA, and non-coding RNAs that are protected from the extracellular environment, which can be utilized as biomarkers. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).